Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

Efficacy of PTCy after mismatched unrelated donor (MMUD) HCT is unknown. In this pilot clinical trial, we enrolled 38 patients with hematologic malignancies scheduled to undergo MMUD-HCT (≥6/8 HLA-matched donors) onto 1 of 2 conditioning strata: myeloablative using fludarabine and fractionated total...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Al Malki, Monzr M., Tsai, Ni-Chun, Palmer, Joycelynne, Mokhtari, Sally, Tsai, Weimin, Cao, Thai, Ali, Haris, Salhotra, Amandeep, Arslan, Shukaib, Aldoss, Ibrahim, Karras, Nicole, Karanes, Chatchada, Zain, Jasmine, Khaled, Samer, Stein, Anthony, Snyder, David, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270662/
https://ncbi.nlm.nih.gov/pubmed/34156440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004192
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi